0H79 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong, Low-debt Balance SheetMinimal leverage and a substantially expanded capital base provide financial flexibility for clinical development. This reduces near-term balance-sheet risk and gives Oruka more capacity to fund programs or pursue partnerships.
Experienced Commercial Leadership AddedHiring a dermatology and immunology commercialization veteran strengthens preparation for potential product launches. It may improve future market-access, launch-planning and partnering capabilities as clinical assets advance.
Broader IL-23 License ScopeA broader licensed field increases the potential applications and strategic flexibility of the IL-23 platform, including ORKA-001. This could support development optionality and future partnering across multiple indications.
Bears Say
Pre-revenue Business ModelOruka has no recurring product revenue because its therapies remain in clinical development. Until commercialization or partnering inflows emerge, the company lacks an operating revenue base to offset research, development and corporate costs.
Widening Operating And Net LossesExpanding losses indicate that development spending is increasing ahead of any commercial return. Continued deterioration in profitability can pressure capital efficiency and raise the funding required before clinical assets generate meaningful economic value.
Accelerating Cash BurnThe worsening cash outflow increases dependence on future financing, equity issuance or partnering proceeds. Even with low debt, sustained clinical spending could reduce financial flexibility if programs take longer to advance or monetization is delayed.
Oruka Therapeutics News
0H79 FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $6.10B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Aug 10, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.038.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics does not currently pay dividends.
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.6.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 66,209,700 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in GB:0H79
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.40 (― Upside)
$156.40 (― Upside)
Blogger Sentiment
Bullish
GB:0H79 Sentiment 60%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $300.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
488.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
218.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
0H79 Stock 12 Month Forecast
Average Price Target
―Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―